Comparative Pharmacology
Head-to-head clinical analysis: DEXAMETHASONE INTENSOL versus EOHILIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAMETHASONE INTENSOL versus EOHILIA.
DEXAMETHASONE INTENSOL vs EOHILIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects via inhibition of phospholipase A2, reduction of prostaglandins and leukotrienes, and modulation of gene transcription.
EOHILIA (budesonide) is a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines and arachidonic acid metabolites, thereby reducing inflammation in the esophagus.
0.75-9 mg/day orally in divided doses every 6-12 hours; for anti-inflammatory/immunosuppressive effects, initial dose 0.75-9 mg/day; for cerebral edema, 10 mg IV then 4 mg IM/IV every 6 hours.
For adults: 0.5 mg/kg IV every 2 weeks, infused over 60 minutes. Maximum single dose: 40 mg.
None Documented
None Documented
Terminal elimination half-life: 36-54 hours (adults); clinically, biological half-life (duration of HPA axis suppression) is longer (24-72 hours).
Terminal elimination half-life is 52 hours (steady state reached after 10-12 days of daily dosing)
Renal (approximately 65-80% as metabolites, <10% as unchanged drug); biliary/fecal (minor).
Renal (70% unchanged drug), fecal (12%) and biliary (5%)
Category D/X
Category C
Corticosteroid
Corticosteroid